Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials)

Influenza and other Respiratory Viruses

Volumn 2, Issue 6, 2008, Pages 203-209

  Rudenko, Larisa ^a   Desheva, Julia ^a   Korovkin, Sergey ^b   Mironov, Alexander ^b   Rekstin, Andrey ^a   Grigorieva, Elena ^a   Donina, Svetlana ^a   Gambaryan, Alexandra ^c   Katlinsky, Anton ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b 'Microgen'   (Russian Federation)

^c CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

Author keywords

Live attenuated influenza vaccine; Pandemic

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; PLACEBO;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BINDING AFFINITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; FEVER; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS A H5N2; MALE; NAUSEA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; REVACCINATION; SEROCONVERSION; SINGLE DRUG DOSE; T LYMPHOCYTE; THROAT IRRITATION; VIRUS STRAIN;

EID: 58149340056     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2008.00056.x     Document Type: Article

References (17)

1. Rudenko LG, Slepushkin AN, Monto AS et al. Efficacy of live attenuated and inactivated influenza vaccines in school children and their inactivated contacts in Novgorod, Russia. J Infect Dis 1993; 168:881-887.
2. Rudenko LG, Alexandrova GI. Current strategies for the prevention of influenza by the Russian cold-adapted live influenza vaccine among different populations; in Osterhaus ADME, Cox N, Hampson AW, (ed): Options for the Control of Influenza IV. Amsterdam: Exerpta Medica, 945-950, 2001.
3. Desheva JA, Lu XH, Rekstin AR et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 2006; 24:6859-6866.
4. Lu X, Edwards LE, Desheva JA et al. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 24:6588-6593.
5. Subbarao K, Chen H, Swayne D et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003; 305:192-200.
6. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-1351.
7. Suguitan AL, McAuliffe J, Mills KL et al. Live, attenuated Influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3:1541-1555.
8. Kendal AP, Maassab HF, Alexandrova GI, Ghendon Y. Development of cold-adapted recombinant live, attenuated influenza vaccines in USA and USSR. Antiviral Res 1981; 1:339-365.
9. Klimov AI, Cox NJ. PCR restriction analysis of genome composition and stability of cold-adapted reassortant live influenza vaccines. J Virol Methods 1995; 52:41-49.
10. Gambaryan AS, Tuzikov AB, Bovin NV et al. Differences between influenza virus receptors on target cells duck and chicken and receptor specificity of the 1997 H5N1 chicken and human influenza viruses from Hong Kong. Arch Virol 2002; 147:1107-1208.
11. World Health Organization. WHO manual on animal influenza diagnosis and surveillance. WHO/CDS/CSR/NCS/2002.5.(http://www.who.int/csr/resourses/ publications/influenza/en/whocdscsrncs20025rev.pdf). [accessed 20 September 2008].
12. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A(H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-943.
13. Rudenko LG. Live attenuated cold-adapted influenza vaccine in Russia: advantages, further research and development; in Katz JM (ed): Options for the Control of Influenza VI. London, Atlanta: International Medical Press, 122-124, 2008.
14. Palker T, Kiseleva I, Johnston K et al. Protective efficacy of intranasal cold-adapted influenza A/New Caledonia/20/99 (H1N1) vaccines comprised of egg- or cell culture-derived reassortants. Virus Res 2004; 105:183-194.
15. World Health Organization. Options for live influenza vaccines (LAIV) in the control of epidemic and pandemic influenza, 12-13 June 2007, Rudenko L.G. Fifty years historical experience with live attenuated vaccines in Russia (http://www.who.int/vaccine_research/diseases/influenza/ Rudenko_50_years_experience.pdf). [accessed 20 September 2006].
16. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by Influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005; 58:195-207.
17. World Health Organization. Global pandemic influenza action plan to increase vaccine supply. WHO/CDS/EPR/GIP/2006.1. September 2006. (http://www.who.int/vaccines-documents/DocsPDF06/863.pdf) [accessed 20 September 2006].